Information needs on breast cancer genetic and non-genetic risk factors in relatives of women with a BRCA1/2 or PALB2 pathogenic variant.


Journal

Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 15 06 2021
revised: 29 07 2021
accepted: 21 08 2021
pubmed: 30 8 2021
medline: 28 12 2021
entrez: 29 8 2021
Statut: ppublish

Résumé

Comprehensive breast cancer (BC) risk models integrating effects of genetic (GRF) and non-genetic risk factors (NGRF) may refine BC prevention recommendations. We explored the perceived information received on BC risk factors, and related characteristics, in female relatives of women with a BRCA1/2 or PALB2 pathogenic variant, undergoing BC risk assessment using the CanRisk© prediction tool. Of 200 consecutive cancer-free women approached after the initial genetic consultation, 161 (80.5%) filled in questionnaires on their perception of information received and wished further information on BC risk factors (e.g., being a carrier of a moderate risk altered gene, personal genetic profile, lifestyles). Multilevel multivariate linear models were performed accounting for the clinician who met the counselee and exploring the effect of counselees' socio-demographic, familial and psychological characteristics on the perceived extent of information received. Perceived no/little information received and wish for further information were more frequent for NGRF (>50%) than for GRF, especially high-risk genes (<20%). Perceived amount of information received and desire for further information were inversely correlated (p=<0.0001). Higher education level related to lower perceived levels of information received on GRF. Younger counselees' age (β = 0.13, p = 0.02) and less frequent engagement coping (e.g., inclination to solicit information) (β = 0.24, p = 0.02) related to lower perceived information received about NGRF. Other assessed counselees' features were not found to be associated to GRF and NGRF information perception. Awareness of counselees' perceived lack of information on BC risk factors indicates a need to enhance evidence-based information on BC NGRF especially.

Identifiants

pubmed: 34455229
pii: S0960-9776(21)00441-0
doi: 10.1016/j.breast.2021.08.011
pmc: PMC8403756
pii:
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
Fanconi Anemia Complementation Group N Protein 0
PALB2 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

38-44

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

J Adolesc Health. 2019 Jan;64(1):116-123
pubmed: 30301677
Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):380-394
pubmed: 29382703
Psychooncology. 2019 Aug;28(8):1679-1686
pubmed: 31152683
Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):15
pubmed: 29508148
Breast Care (Basel). 2018 Apr;13(2):109-114
pubmed: 29887787
BMJ Open. 2017 Dec 22;7(12):e017675
pubmed: 29275340
J Adv Nurs. 2017 Apr;73(4):760-774
pubmed: 27653812
Patient Educ Couns. 2021 Feb;104(2):257-264
pubmed: 32988685
Br J Cancer. 2002 May 6;86(9):1373-8
pubmed: 11986766
Br J Psychiatry. 1990 Jan;156:79-83
pubmed: 2297623
Fam Cancer. 2020 Oct;19(4):297-306
pubmed: 32430685
J Clin Oncol. 2007 Aug 20;25(24):3705-11
pubmed: 17704419
Eur J Cancer. 2010 Oct;46(15):2726-38
pubmed: 20674333
J Psychosoc Oncol. 2008;26(3):63-80
pubmed: 19042265
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
Psychooncology. 2008 Aug;17(8):746-55
pubmed: 18615871
PLoS One. 2020 Mar 6;15(3):e0229999
pubmed: 32142536
Health Educ Monogr. 1978 Winter;6(4):394-405
pubmed: 299611
J Genet Couns. 2016 Apr;25(2):218-27
pubmed: 26259529
Breast. 2018 Jun;39:139-147
pubmed: 29610032
BMJ. 2020 Oct 28;371:m3873
pubmed: 33115755
Diagnostics (Basel). 2020 Jul 20;10(7):
pubmed: 32698375
Patient Educ Couns. 2021 Apr;104(4):726-731
pubmed: 33455827
J Clin Oncol. 2006 Feb 1;24(4):700-6
pubmed: 16446344
N Engl J Med. 2021 Feb 4;384(5):428-439
pubmed: 33471991
Psychooncology. 2019 May;28(5):1056-1062
pubmed: 30848018
Psychooncology. 2020 Mar;29(3):550-556
pubmed: 31823434
Eur J Cancer Prev. 2019 Nov;28(6):515-521
pubmed: 30681416
J Public Health (Oxf). 2017 Mar 1;39(1):113-121
pubmed: 26834190
J Pers Soc Psychol. 1989 Feb;56(2):267-83
pubmed: 2926629
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Fam Cancer. 2011 Mar;10(1):87-96
pubmed: 20852944
J Genet Couns. 2017 Dec;26(6):1179-1196
pubmed: 28667568
Encephale. 2003 Nov-Dec;29(6):507-18
pubmed: 15029085
Cancer Causes Control. 2015 Mar;26(3):333-44
pubmed: 25579073
Int J Environ Res Public Health. 2018 Feb 12;15(2):
pubmed: 29439543
Lancet. 2012 Dec 15;380(9859):2224-60
pubmed: 23245609
J Pers Soc Psychol. 1984 Apr;46(4):839-52
pubmed: 6737195
Public Health Genomics. 2011;14(3):178-89
pubmed: 21464556
J Genet Couns. 2018 Jun;27(3):702-708
pubmed: 29168041
Transl Behav Med. 2019 May 16;9(3):493-503
pubmed: 31094441
Breast Cancer Res. 2020 Feb 17;22(1):21
pubmed: 32066492
Breast Cancer Res. 2005;7(5):R833-43
pubmed: 16168130
Fam Cancer. 2019 Apr;18(2):147-152
pubmed: 30251170
Genet Med. 2020 Nov;22(11):1803-1811
pubmed: 32624571
Psychooncology. 2018 Aug;27(8):1908-1914
pubmed: 29677398
J Natl Cancer Inst. 2014 Jun;106(6):dju091
pubmed: 24824314
Future Oncol. 2010 May;6(5):691-707
pubmed: 20465385
J Womens Health (Larchmt). 2018 Feb;27(2):162-170
pubmed: 28472603
J Health Commun. 2019;24(4):377-384
pubmed: 31060454
Int J Behav Med. 2019 Feb;26(1):85-90
pubmed: 30088188
J Community Genet. 2019 Oct;10(4):481-487
pubmed: 30877488
JCO Precis Oncol. 2021 Jan 28;5:
pubmed: 34036224
Healthcare (Basel). 2016 Jun 28;4(3):
pubmed: 27417623
J Genet Couns. 2021 Jun;30(3):701-709
pubmed: 33174380
PLoS One. 2014 Nov 25;9(11):e112733
pubmed: 25423095

Auteurs

Anne Brédart (A)

Institut Curie, Supportive Care Department, Psycho-oncology Unit, PSL University, 26 rue d'Ulm, Paris, 75005 Paris Cedex 05, France; University of Paris, 71 Avenue Edouard Vaillant, Boulogne-Billancourt, 92774, France. Electronic address: anne.bredart@curie.fr.

Antoine De Pauw (A)

Institut Curie, Cancer Genetic Clinic, PSL University, 26 rue d'Ulm, 75005 Paris Cedex 05, France.

Amélie Anota (A)

Centre Léon Bérard, Department of Clinical Research and Innovation& Human and Social Sciences Department, 28 rue Laennec, Lyon; French National Platform Quality of Life and Cancer, Lyon, 69373, France.

Anja Tüchler (A)

Center for Familial Breast and Ovarian and Cancer for Integrated Oncology (CIO), Kerpener Str. 62 50937 Cologne, University Hospital of Cologne, Cologne, Germany.

Julia Dick (J)

Center for Familial Breast and Ovarian and Cancer for Integrated Oncology (CIO), Kerpener Str. 62 50937 Cologne, University Hospital of Cologne, Cologne, Germany.

Anita Müller (A)

Institut Curie, Supportive Care Department, Psycho-oncology Unit, PSL University, 26 rue d'Ulm, Paris, 75005 Paris Cedex 05, France; VCR, École de Psychologues Praticiens de l'Institut Catholique de Paris, 23 Rue du Montparnasse, 75006, Paris, France.

Jean-Luc Kop (JL)

Université de Lorraine, 2LPN, 3 Place Godefroy de Bouillon, Nancy, 54 015 Nancy Cedex, France.

Kerstin Rhiem (K)

Center for Familial Breast and Ovarian and Cancer for Integrated Oncology (CIO), Kerpener Str. 62 50937 Cologne, University Hospital of Cologne, Cologne, Germany.

Rita Schmutzler (R)

Center for Familial Breast and Ovarian and Cancer for Integrated Oncology (CIO), Kerpener Str. 62 50937 Cologne, University Hospital of Cologne, Cologne, Germany.

Peter Devilee (P)

Leiden University Medical Centre, Department of Human Genetics, Department of Pathology, S4-P, P.O. Box 9600, 2300, RC, Leiden, the Netherlands.

Dominique Stoppa-Lyonnet (D)

Institut Curie, Cancer Genetic Clinic, PSL University, 26 rue d'Ulm, 75005 Paris Cedex 05, France.

Sylvie Dolbeault (S)

Institut Curie, Supportive Care Department, Psycho-oncology Unit, PSL University, 26 rue d'Ulm, Paris, 75005 Paris Cedex 05, France; CESP, University Paris-Sud, UVSQ, INSERM, University Paris-Saclay, 16 Avenue Paul Vaillant-Couturier, 94807, Villejuif Cedex, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH